Here, a transgenic model was employed with artificial overexpression of CysLT2 in endothelial cells and, as in most previous investigations, the potential impact of pre-existing vascular disease or atherosclerosis was not addressed. The gene discussed is CYSLTR2; the disease is atherosclerosis.